Scholar Rock Holding Corp SRRK
We take great care to ensure that the data presented and summarized in this overview for Scholar Rock Holding Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRRK
View all-
Siren, L.L.C. New York, NY11.3MShares$504 Million4.51% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.65MShares$388 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA6.79MShares$304 Million31.52% of portfolio
-
Black Rock Inc. New York, NY5.66MShares$254 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA5.24MShares$235 Million2.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.03MShares$181 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X02.94MShares$132 Million0.14% of portfolio
-
State Street Corp Boston, MA2.77MShares$124 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.41MShares$108 Million0.34% of portfolio
-
Hood River Capital Management LLC Palm Beach Gardens, FL2.35MShares$105 Million0.35% of portfolio
Latest Institutional Activity in SRRK
Top Purchases
Top Sells
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SRRK
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 10
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
1,600,000
-14.75%
|
$65,600,000
$41.65 P/Share
|
Nov 25
2024
|
Invus Public Equities, L.P. |
SELL
Open market or private sale
|
Direct |
409,433
-0.74%
|
$15,967,887
$39.34 P/Share
|
Nov 25
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,375
-2.06%
|
$248,625
$39.49 P/Share
|
Nov 25
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,375
+7.45%
|
$51,000
$8.59 P/Share
|
Nov 22
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,145
-2.86%
|
$64,350
$30.01 P/Share
|
Nov 22
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,145
+2.78%
|
$17,160
$8.59 P/Share
|
Nov 12
2024
|
Michael Gilman |
BUY
Bona fide gift
|
Direct |
37,459
+42.37%
|
-
|
Nov 12
2024
|
Michael Gilman |
SELL
Bona fide gift
|
Indirect |
37,459
-100.0%
|
-
|
Nov 11
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,105
-2.81%
|
$63,150
$30.0 P/Share
|
Nov 11
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,105
+2.73%
|
$16,840
$8.59 P/Share
|
Oct 08
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
37,187
-18.76%
|
$1,264,358
$34.9 P/Share
|
Oct 08
2024
|
Edward H Myles COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,187
+15.79%
|
$371,870
$10.0 P/Share
|
Oct 07
2024
|
Edward H Myles COO & CFO |
SELL
Open market or private sale
|
Direct |
206,240
-18.28%
|
$5,568,480
$27.19 P/Share
|
Oct 07
2024
|
Edward H Myles COO & CFO |
SELL
Exercise of conversion of derivative security
|
Direct |
206,240
-35.96%
|
$2,681,120
$13.83 P/Share
|
Oct 07
2024
|
Tracey Sacco CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
30,000
-19.6%
|
$750,000
$25.91 P/Share
|
Oct 07
2024
|
Tracey Sacco CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+27.45%
|
$300,000
$10.0 P/Share
|
Oct 07
2024
|
Srinivas Akkaraju |
SELL
Open market or private sale
|
Indirect |
1,175,713
-6.11%
|
$35,271,390
$30.0 P/Share
|
Oct 07
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
109,375
-24.77%
|
$2,953,125
$27.29 P/Share
|
Oct 07
2024
|
Jing L. Marantz CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
109,375
+37.51%
|
$875,000
$8.59 P/Share
|
Sep 16
2024
|
Mo Qatanani CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,936
-1.34%
|
$15,488
$8.58 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 705K shares |
---|---|
Bona fide gift | 37.5K shares |
Other acquisition or disposition | 112K shares |
Exercise of conversion of derivative security | 200K shares |
Bona fide gift | 58.8K shares |
---|---|
Open market or private sale | 3.66M shares |
Other acquisition or disposition | 599K shares |
Exercise of conversion of derivative security | 206K shares |